ADMA Biologics Faces Lawsuit Over Revenue Claims

ADMA Biologics is in hot water after its stock took a nosedive, dropping 29%, due to claims of channel stuffing made by Culper Research. This has led to a class action lawsuit against the company for allegedly misleading investors about its revenue growth, which was reported as 20% but might have actually been a decline of 3% in 2025. Investors have until August 10, 2026, to get involved in the lawsuit. What does it mean for you? If you have invested in ADMA Biologics, you might want to check your portfolio and consider joining the lawsuit, as you could potentially recover some of your losses.